Pharmaron

Forecast & Rating12 analysts currently cover Pharmaron, with about 75.0% giving a positive rating — meaning they expect the stock to rise. The average price target is ¥38.15, about 21.3% downside from the current price of ¥48.45. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 65.5% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Pharmaron closely still see room for the stock to rise. Data as of Aug 11, 2026; for reference only and not investment advice.